These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37563749)

  • 1. Pneumocystis jirovecii pneumonia after CD4+ T-cell recovery subsequent to CD19-targeted chimeric antigen receptor T-cell therapy: A case report and brief review of literature.
    Kawata K; Shima H; Shinjoh M; Yamazaki F; Kurosawa T; Yaginuma M; Takada H; Shimada H
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1885. PubMed ID: 37563749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
    Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
    Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
    Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
    Geerlinks AV; Campigotto A; Science M; Gupta S
    Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
    Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
    BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
    Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
    Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis jirovecii Pneumonia in a Liver Transplant Recipient With an Adverse Reaction to Trimethoprim/Sulfamethoxazole Treated With a Sulfonamide Desensitization Protocol: Case Report.
    Baran K; Furmańczyk-Zawiska A; Wieczorek-Godlewska R; Nitek P; Durlik M
    Transplant Proc; 2024 May; 56(4):1000-1005. PubMed ID: 38760300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
    Avino LJ; Naylor SM; Roecker AM
    Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
    Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
    BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
    Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
    Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous
    Sood N; Vadnerkar A; Kodali M; Hamacher LK
    Eur J Case Rep Intern Med; 2024; 11(7):004615. PubMed ID: 38984179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible myoclonus, asterixis, and tremor associated with high dose trimethoprim-sulfamethoxazole: a case report.
    Gray DA; Foo D
    J Spinal Cord Med; 2016; 39(1):115-7. PubMed ID: 26111222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
    Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
    BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
    Dilworth TJ; Ibrahim OM; Mercier RC
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia.
    Nazir HF; Elshinawy M; AlRawas A; Khater D; Zadjaly S; Wali Y
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):203-208. PubMed ID: 28234744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.